Searched for: in-biosketch:true
person:bangas01
Complete revascularization in contemporary practice
Bangalore, Sripal
PMID: 23424268
ISSN: 1941-7640
CID: 223302
Treatment-resistant hypertension: another Cinderella story
Messerli, Franz H; Bangalore, Sripal
PMID: 23386710
ISSN: 0195-668x
CID: 218532
beta-Blocker use for patients with or at risk for coronary artery disease--reply [Letter]
Bangalore, Sripal; Steg, P Gabriel; Bhatt, Deepak L
PMID: 23385261
ISSN: 0098-7484
CID: 218542
Efficacy and safety of dual calcium channel blockade for the treatment of hypertension: a meta-analysis
Alviar, Carlos L; Devarapally, Santhosh; Nadkarni, Girish N; Romero, Jorge; Benjo, Alexandre M; Javed, Fahad; Doherty, Bryan; Kang, Hyuensok; Bangalore, Sripal; Messerli, Franz H
BACKGROUND Dual calcium-channel blocker (CCB) with a dihydropyridine (DHP) and a nondihydropyridine (NDHP) has been proposed for hypertension treatment. However, the safety and efficacy of this approach is not well known. METHODS A MEDLINE/EMBASE/CENTRAL search for randomized clinical trials published on this topic from 1966 to February 2012 was performed. Efficacy outcomes of decrease in systolic (SBP) and diastolic (DBP) blood pressures from baseline, changes in heart rate (HR), and adverse effects were compared between dual CCB therapy vs. DHP or NDHP. SBP, DBP, and HR were expressed as weighted mean deviation (WMD). RESULTS A total of 6 studies with 153 patients were included. Dual CCB produced a significantly greater reduction in SBP (21.6+/-9.2 mmHg) from baseline than DHP (10.3+/-6.3 mmHg (WMD = 10.9 mmHg, P < 0.0001)) or NDHP (8.9+/-4.2 mmHg (WMD = 14.1 mmHg, P = 0.002)). Dual CCB therapy reduced DBP from baseline more than either monotherapy (dual CCB = 17.5+/-10.2 mmHg vs. DHP = 11.6+/-8.7 mmHg, WMD = 5.5 mmHg, P < 0.001; and NDHP = 10.5+/-5.6 mmHg, WMD = 5.3 mmHg, P = 0.03). Dual CCB therapy had significantly lower HR compared to DHP (P < 0.001) but was comparable to NDHP (P = 0.12) (Delta change dual CCB = -4.0+/-3.5 vs. DHP = -2.0+/-1.5 and NDHP = -6.0+/-5.0 beats/min). Dual CCB therapy did not increase adverse effects. CONCLUSIONS Dual CCB therapy lowers blood pressure significantly better than CCB monotherapy, without an increase in adverse events. However, given the lack of long-term outcome data on efficacy and safety, dual CCB therapy should be used with restraint, if at all. Large-scale long-term trials are needed to further evaluate such a strategy.
PMID: 23382415
ISSN: 0895-7061
CID: 218552
Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials
Makani, Harikrishna; Bangalore, Sripal; Desouza, Kavit A; Shah, Arpit; Messerli, Franz H
OBJECTIVE: To compare the long term efficacy and adverse events of dual blockade of the renin-angiotensin system with monotherapy. DESIGN: Systematic review and meta-analysis. DATA SOURCES: PubMed, Embase, and the Cochrane central register of controlled trials, January 1990 to August 2012. STUDY SELECTION: Randomised controlled trials comparing dual blockers of the renin-angiotensin system with monotherapy, reporting data on either long term efficacy (>/=1 year) or safety events (>/=4 weeks), and with a sample size of at least 50. Analysis was stratified by trials with patients with heart failure versus patients without heart failure. RESULTS: 33 randomised controlled trials with 68 405 patients (mean age 61 years, 71% men) and mean duration of 52 weeks were included. Dual blockade of the renin-angiotensin system was not associated with any significant benefit for all cause mortality (relative risk 0.97, 95% confidence interval 0.89 to 1.06) and cardiovascular mortality (0.96, 0.88 to 1.05) compared with monotherapy. Compared with monotherapy, dual therapy was associated with an 18% reduction in admissions to hospital for heart failure (0.82, 0.74 to 0.92). However, compared with monotherapy, dual therapy was associated with a 55% increase in the risk of hyperkalaemia (P<0.001), a 66% increase in the risk of hypotension (P<0.001), a 41% increase in the risk of renal failure (P=0.01), and a 27% increase in the risk of withdrawal owing to adverse events (P<0.001). Efficacy and safety results were consistent in cohorts with and without heart failure when dual therapy was compared with monotherapy except for all cause mortality, which was higher in the cohort without heart failure (P=0.04 v P=0.15), and renal failure was significantly higher in the cohort with heart failure (P<0.001 v P=0.79). CONCLUSION: Although dual blockade of the renin-angiotensin system may have seemingly beneficial effects on certain surrogate endpoints, it failed to reduce mortality and was associated with an excessive risk of adverse events such as hyperkalaemia, hypotension, and renal failure compared with monotherapy. The risk to benefit ratio argues against the use of dual therapy.
PMCID:3556933
PMID: 23358488
ISSN: 0959-8138
CID: 218562
ALTITUDE Trial and Dual RAS Blockade: The Alluring but Soft Science of the Surrogate End Point
Messerli, Franz H; Bangalore, Sripal
PMID: 23332648
ISSN: 0002-9343
CID: 218572
Percutaneous Coronary Intervention versus Optimal Medical Therapy for Prevention of Spontaneous Myocardial Infarction in Subjects with Stable Ischemic Heart Disease
Bangalore, Sripal; Pursnani, Seema; Kumar, Sunil; Bagos, Pantelis G
BACKGROUND: Contemporary studies have shown that spontaneous but not procedural myocardial infarction (MI) are related to subsequent mortality. Whether PCI reduces spontaneous (non-procedural) MI is unknown. METHODS AND RESULTS: PUBMED, EMBASE, and CENTRAL were searched for randomized clinical trials (RCTs), until October 2012, comparing PCI with OMT, for stable ischemic heart disease, and reporting MI outcomes - spontaneous non-procedural MI, procedural MI and all MI including procedure related MI. Given the varying length of follow-up between trials, a mixed-effect poisson regression meta-analysis was employed. From 12 RCTs with 37548 patient-years of follow-up, PCI, when compared with OMT alone, was associated with significant lower incident rate ratio (IRR) for spontaneous non-procedural MI (IRR=0.76, 95% CI 0.58-0.99) at the risk of higher procedural MI (IRR=4.11, 95% CI 2.53-6.88) without any difference in all MI (IRR=0.96, 95% CI 0.74-1.21). The point estimate for PCI vs. OMT for all-cause mortality (IRR=0.88, 95% CI 0.75-1.03) and cardiovascular mortality (IRR=0.70, 95% CI 0.44-1.09) paralleled that of spontaneous non-procedural MI (but not procedural or all nonfatal MI) although these were not statistically significant. CONCLUSIONS: PCI compared to OMT reduced spontaneous MI at the risk of procedural MI without any difference in all MI. Consistent with prior studies showing that spontaneous MI but not procedural MI are related to subsequent mortality, in the present report the point estimate for reduced mortality with PCI compared to OMT paralleled the prevention of spontaneous MI with PCI. Further studies are needed to determine whether these associations are causal.
PMID: 23325526
ISSN: 0009-7322
CID: 218582
When Conventional Heart Failure Therapy is not Enough: Angiotensin Receptor Blocker, Direct Renin Inhibitor, or Aldosterone Antagonist?
Bangalore, Sripal; Kumar, Sunil; Messerli, Franz H
In patients on conventional heart failure therapy including angiotensin-converting enzyme (ACE) inhibitors, the addition of angiotensin receptor blockers (ARBs), direct renin inhibitors (DRIs), or aldosterone antagonists are therapeutic options to further reduce the risk of cardiovascular events. However, whether one is preferable over the other is not known. PubMed, EMBASE, and Cochrane Central Register of Controlled Trials databases were searched for randomized clinical trials (RCTs), until March 2011, of trials testing either an ARB, DRI, or an aldosterone antagonist in patients with heart failure who were on conventional heart failure therapy with follow-up of at least 3 months. Efficacy (death, cardiovascular death, nonfatal myocardial infarction, heart failure hospitalization and composite of cardiovascular death or heart failure hospitalization) and safety (hyperkalemia, hypotension, renal failure) outcomes were compared. The authors identified 16 RCTs involving 31,429 participants that satisfied the inclusion criteria. When compared with placebo (reference rate ratio [RR] of 1), aldosterone antagonists reduced the rate of death (RR, 0.79; 95% credibility interval [CrI], 0.66-0.98), cardiovascular death (RR, 0.78; 95% CrI, 0.65-0.93), heart failure hospitalization (RR, 0.74; 95% CrI, 0.55-0.94), and the composite of cardiovascular death or heart failure hospitalization (RR, 0.73; 95% CrI, 0.55-0.90) with no difference for other efficacy outcomes. However, ARBs and DRIs did not result in any significant reduction in the rate of any of the efficacy outcomes when compared with placebo. When compared with placebo (RR=1), ARBs increased the rate of hyperkalemia (138% increase), renal failure (126% increase), and hypotension (63% increase). Similarly, aldosterone antagonists resulted in a 110% increase in hyperkalemia and DRIs with a 98% increase in hypotension. In patients with heart failure and reduced systolic function on conventional heart failure medications, the risk benefit ratio favors the addition of aldosterone antagonists over ARBs or DRIs.
PMID: 23241032
ISSN: 1527-5299
CID: 218592
Diuretic-based regimens for obese patients?
Messerli, Franz H; Bangalore, Sripal
PMID: 23219285
ISSN: 0140-6736
CID: 218602
Early intravenous beta-blockers in patients with acute coronary syndrome-A meta-analysis of randomized trials
Chatterjee, Saurav; Chaudhuri, Debanik; Vedanthan, Rajesh; Fuster, Valentin; Ibanez, Borja; Bangalore, Sripal; Mukherjee, Debabrata
BACKGROUND: Intravenous (IV) beta-blockade is currently a Class IIa recommendation in early management of patients with acute coronary syndromes (ACS) without obvious contraindications. METHODS: We searched the PubMed, EMBASE and the Cochrane Register for Controlled Clinical Trials for randomized clinical trials from 1965 through December, 2011, comparing intravenous beta-blockers administered within 12hours of presentation of ACS with standard medical therapy and/or placebo. The primary outcome assessed was the risk of short-term (in-hospital mortality-with maximum follow up duration of 90days) all-cause mortality in the intervention group versus the comparator group. The secondary outcomes assessed were ventricular tachyarrhythmias, myocardial reinfarction, cardiogenic shock, and stroke. Pooled treatment effects were estimated using relative risk with Mantel-Haenszel risk ratio, using a random-effects model. RESULTS: Sixteen studies enrolling 73,396 participants met the inclusion exclusion criteria. In- hospital mortality was reduced 8% with intravenous beta-blockers, RR=0.92 (95% CI, 0.86-1.00; p=0.04) when compared with controls. Moreover, intravenous beta-blockade reduced the risk of ventricular tachyarrhythmias (RR=0.61; 95 % CI 0.47-0.79; p=0.0003) and myocardial reinfarction (RR=0.73, 95 % CI 0.59-0.91; p=0.004) without increase in the risk of cardiogenic shock, (RR=1.02; 95% CI 0.77-1.35; p=0.91) or stroke (RR=0.58; 95 % CI 0.17-1.98; p=0.38). CONCLUSIONS: Intravenous beta-blockers early in the course of appropriate patients with ACS appears to be associated with significant reduction in the risk of short-term cardiovascular outcomes, including a reduction in the risk of all-cause mortality.
PMCID:4104797
PMID: 23168009
ISSN: 0167-5273
CID: 218612